VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZLAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ZLABZai Lab Limited
$19.35$2.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ZLAB logoZai Lab Limited(ZLAB)Earnings, Financials & Key Ratios

ZLAB•NASDAQ
$19.35
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCommercial Specialty Pharma
AboutZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.Show more
  • Revenue$460M+15.3%
  • EBITDA-$209M+20.3%
  • Net Income-$176M+31.7%
  • EPS (Diluted)-1.60+38.5%
  • Gross Margin58.47%-7.1%
  • EBITDA Margin-45.32%+30.9%
  • Operating Margin-48.59%+31.3%
  • Net Margin-38.15%+40.8%
  • ROE-22.56%+28.2%

ZLAB Price & Volume

Zai Lab Limited (ZLAB) stock price & volume — 10-year historical chart

Loading chart...

Stagnating Revenue Growth Amidst Persistent Operational Losses

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Persistent Capital Market Dependency

Key Thesis Takeaways

  • Zai Lab's reliance on a license-and-commercialize model faces significant sustainability challenges as revenue growth turned negative with a 6.5% year-over-year contraction in 2026Q1.
  • The company continues to struggle with achieving operating leverage, evidenced by persistent quarterly operating losses of $69.3 million and a reliance on stock-based compensation exceeding $13 million per quarter to manage expenses.
  • Investors should monitor the company's ability to stabilize its cash position, which has declined from $790.2 million in 2023Q4 to $651.3 million, as rising debt levels and capital erosion threaten long-term financial flexibility.

Verdict Logic

the company's inability to achieve operational profitability, combined with a 6.5% revenue decline and a rising debt-to-equity ratio of 0.35, suggests significant ongoing capital risk.

ZLAB Growth Metrics

Zai Lab Limited (ZLAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years56.54%
3 Years28.86%
TTM8.36%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM29.34%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM87.93%

Return on Capital

10 Years-46.86%
5 Years-36.85%
3 Years-32.78%
Last Year-27.22%

ZLAB Recent Earnings

Zai Lab Limited (ZLAB) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.46+12.6%
$0.53
Rev
$100M-8.1%
$108M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.46-4.5%
$0.44
Rev
$128M+4.4%
$122M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.33-17.9%
$0.28
Rev
$116M-8.4%
$127M
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.37+0.0%
$0.37
Rev
$110M-26.8%
$150M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.46vs $0.53+12.6%
$100Mvs $108M-8.1%
Q1 2026Feb 26, 2026
$0.46vs $0.44-4.5%
$128Mvs $122M+4.4%
Q4 2025Nov 6, 2025
$0.33vs $0.28-17.9%
$116Mvs $127M-8.4%
Q3 2025Aug 7, 2025
$0.37vs $0.37+0.0%
$110Mvs $150M-26.8%
Based on last 12 quarters of dataView full earnings history →

Latest ZLAB News

Recent stock market news and headlines for Zai Lab Limited (ZLAB)

Business Wire·Jun 16, 2026
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of pulmonary neuroendocrine carcinomas (NECs). The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Pro.

Peers Comparison

Key metrics vs top competitors for Zai Lab Limited (ZLAB)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ZLAB logoZLABZai Lab LimitedCurrent
$19.35$2.14B-12.0915.33%-38.15%-22.56%—
LEGN logoLEGNLegend Biotech Corporation
$27.68$5.12B-17.3064.04%-21.97%-24.91%—
ZYME logoZYMEZymeworks Inc.
$26.72$1.97B-24.7438.87%-126.33%-0.25%—
CAN logoCANCanaan Inc.
$0.27$169.41M-0.5996.69%-39.68%-60.72%—
RCUS logoRCUSArcus Biosciences, Inc.
$30.25$3.05B-9.19-4.26%-156.36%-68.97%—
IMVT logoIMVTImmunovant, Inc.
$40.09$8.23B-14.47——-68.16%—

Compare ZLAB vs Peers

Zai Lab Limited (ZLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LEGN

Most directly comparable listed peer for ZLAB.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare ZLAB against a more recognizable public peer.

Peer Set

Compare Top 5

vs LEGN, ZYME, CAN, RCUS

ZLAB SEC Filings & Documents

Zai Lab Limited (ZLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Nov 6, 2025·SEC

10-K Annual Reports

2
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when ZLAB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ZLAB Frequently Asked Questions

Zai Lab Limited (ZLAB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Zai Lab Limited's revenue?

Zai Lab Limited (ZLAB) reported $453.3M in revenue for fiscal year 2025.

How fast is Zai Lab Limited growing?

Zai Lab Limited (ZLAB) grew revenue by 15.3% over the past year. This is strong growth.

Is ZLAB profitable?

Zai Lab Limited (ZLAB) reported a net loss of $178.1M for fiscal year 2025.

Dividend & Returns
What is ZLAB's return on equity?

Zai Lab Limited (ZLAB) has a return on equity (ROE) of -22.6%. Negative ROE indicates the company is unprofitable.

What is Zai Lab Limited's free cash flow?

Zai Lab Limited (ZLAB) had negative free cash flow of $129.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ZLAB back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →